Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis (Atreya et al., 2018). The gene discussed is TLR9; the disease is ulcerative colitis.